Sermorelin vs Tamoxifen
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both Sermorelin and Tamoxifen act on estrogen receptors. Receptor competition may reduce effectiveness of one or both. Using multiple SERMs simultaneously is generally not recommended — choose one.
Molecular Data
Sermorelin Tamoxifen
Weight 3,358 Da 371.51 Da
Half-life 10-12 minutes ~5-7 days
Chain 29 amino acids —
Type GHRH analog Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Dosing Protocols
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Tamoxifen
20-40mg oral daily / Once daily
Side Effects
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
Active malignancy
Pituitary tumors
Pregnancy
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
Sermorelin Tamoxifen
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.